In fall 2024, xanomeline trospium chloride (XT) was approved by the U.S. Food and Drug Administration for the treatment of ...

There is a small body of literature that examines neurophysiological indices of the benefits of chronic physical activity participation on cognitive function in young adults; however, the vast ...